AJR. American journal of roentgenology · 1999
Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tepe G, Schott U, Erley C M, Albes J, Claussen C D, Duda S H
Аннотация
OBJECTIVE: This feasibility study was designed to evaluate the therapeutic potential of intraarterial urokinase combined with abciximab, an IV platelet glycoprotein IIb/IIIa receptor antagonist, in peripheral arterial thrombosis.
CONCLUSION: The administration of a highly potent glycoprotein IIb/IIIa inhibitor in conjunction with intraarterial fibrinolysis was safe in 14 patients. One distal embolization and no major bleeding occurred. The primary success rate was 100%. Treatment times ranged from 50 min to 8 hr. We found a reocclusion rate of 7% (1/14) at intermediate follow-up.
CONCLUSION: The administration of a highly potent glycoprotein IIb/IIIa inhibitor in conjunction with intraarterial fibrinolysis was safe in 14 patients. One distal embolization and no major bleeding occurred. The primary success rate was 100%. Treatment times ranged from 50 min to 8 hr. We found a reocclusion rate of 7% (1/14) at intermediate follow-up.
Предметные рубрики MeSH
AbciximabAntibodies, MonoclonalDrug Therapy, CombinationFeasibility StudiesFemaleFemoral ArteryHumansIliac ArteryImmunoglobulin Fab FragmentsInfusions, Intra-ArterialInfusions, IntravenousMaleMiddle AgedPilot ProjectsPlasminogen ActivatorsPlatelet Aggregation InhibitorsThrombolytic TherapyThrombosisUrokinase-Type Plasminogen Activator